RxDoctor Payments Data

Michael Carron, MD

Otolaryngology · Dearborn, MINPI 1568670156

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Microaire Surgical Instruments LLC accounts for 86.0% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $13,853, 2.6 times the $5,382 reported in 2019. Among otolaryngology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,363in general payments, 2019–2025

Across 102 payments — averaging $219.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Microaire Surgical Instruments LLC$19K
  • Optinose US, Inc.$712
  • Biotissue Holdings Inc.$466
  • Medtronic$290
  • Stryker$256
  • Johnson & Johnson$252
  • plus $1K from 19 others

What the payments were for

  • Consulting fees$3,44015%
  • Speaking & faculty fees$12,75057%
  • Travel & lodging$3,08714%
  • Food & beverage$3,07014%
  • Education$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,363 in reported general payments places this provider in the 90th percentile of 257 otolaryngology providers in Michigan.

See all otolaryngology providers in Michigan

Medicare billing

Part B allowed, 2024
$52,162
Medicare patients
146
Services billed
1,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate22$18,674
Azelastine Hcl111$3,178
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth15$1,904
Ipratropium Bromide64$1,815
Clotrimazole49$1,233
Fluticasone Propionate88$1,113
Famotidine21$346
Omeprazole27$315
Montelukast Sodium26$179
Triamcinolone Acetonide15$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$712$18,67422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 257 otolaryngology providers in Michigan.

Other otolaryngology in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →